Objectives. HER2 expression in gastric cancer (GC) has received attention as a potential target for therapy with Trastuzumab. We reviewed the current knowledge on HER2 status in premalignant gastric lesions and in early (EGC) and advanced (AGC) GC to discuss the possible pathogenetic and prognostic roles of HER2 overexpression in GC. Results. HER2 overexpression was documented in gastric low-grade (LG) and high-grade intraepithelial neoplasia (HG-IEN), with higher frequency in gastric type dysplasia. HER2 overexpression was significantly associated with disease recurrence and poor prognosis in EGC representing an independent risk factor for lymph node metastases. HER2 overexpression was more frequent in AGC characterized by high grade, advanced stage, and high Ki-67 labeling index. The discordance in HER2 status was evidenced between primitive GC and synchronous or metachronous metastases. Conclusions. HER2 overexpression in premalignant gastric lesions suggests its potential involvement in the early steps of gastric carcinogenesis. The assessment of HER2 status in EGC may be helpful for the identification of patients who are at low risk for developing nodal metastases. Finally, the possible discordance in HER2 status between primary GC and its synchronous metastases support routine assessment of HER2 both in the primary GC and in its metastatic lesions.
checkpoints [17, 18]. Recently, the Cancer Genome Atlas (TCGA) project classified tumors with CIN as a distinct biomolecular subgroup of GC characterized by the frequent amplification of genes such as HER2, EGFR, MET, FGFR2, and RAS genes (KRAS/NRAS) which are all related to the receptor tyrosine kinase RTK/RAS signaling [19]. In particular, HER2 gene encodes for HER2/erbB2 protein which belongs to the epidermal growth factor receptor family that comprises three other proteins with a similar structure, namely, HER1/erbB1, HER3/erbB3, and HER4/erbB4. HER2 plays an important role in the proliferation and differentiation of normal cells [20] and binding to its ligand gives rise to the creation of homodimers and heterodimers and activation of downstream signaling pathways [20]. Any aberrations in the structure or function of this receptor may lead to uncontrolled cell proliferation, neoplastic development, and progression [20]. Trastuzumab is a humanized monoclonal antibody that selectively targets HER2 receptor and inhibits its downstream signaling pathways in cells with HER2 overexpression [21]. A recent phase III randomized study (ToGA) demonstrated a significant survival benefit in patients affected by advanced GC with HER2 overexpression and treated with combined Trastuzumab and chemotherapy [22]. Hence, in recent years, the evaluation of HER2 overexpression has received attention as a target for novel therapeutic strategies aimed at increasing the survival to GC. In addition, assessment of HER2 status in all GCs at the time of diagnosis has been recommended in order to establish patient eligibility for treatment with Trastuzumab.

In this paper we review the controversial role of HER2 in gastric cancerogenesis and focus on the prevalence and potential prognostic significance of HER2 expression in preneoplastic lesions as well as in early and advanced GC.

2. HER2 in Premalignant Gastric Lesions

Although chronic atrophic gastritis and intestinal metaplasia of the stomach are considered to be preneoplastic lesions of GC, some Japanese studies do not clearly indicate a role in gastric carcinogenesis [23, 24]. Therefore dysplasia of the gastric mucosa represents the only universally accepted precancerous lesion of GC. Dysplasia is characterized by a wide range of cellular and structural atypia and it is defined as intraepithelial neoplasia (IEN), a pathological condition which lies between atrophic gastritis and GC [25]. IEN may develop in the gastric epithelium affected or not by intestinal metaplasia and it can be classified into four categories: indefinite for intraepithelial neoplasia, low-grade intraepithelial neoplasia (LG-IEN), high-grade intraepithelial neoplasia (HG-IEN), and suspicious for invasive cancer [26, 27]. The histological distinction between LG and HG IEN relies on the severity of architectural and cytological atypia. In detail, in LG-IEN the mucosa maintains tubular differentiation and the proliferative zone is limited to the outward portion, while in HG-IEN mucosal architecture is distorted and shows crowded irregular glands with marked cellular atypia and diffuse proliferative activity [28]. HG-IEN is associated with increased risk of GC [28–31]. Compared to LG-IEN, it is characterized by higher frequency of genetic abnormalities, including 8q gain, p53 overexpression, e-cadherin loss, and HER2 amplification, which are also present in invasive GC [32–36].

The possible occurrence of HER2 amplification in precancerous lesions was previously investigated in bronchial and breast epithelia [37–40]. HER2 amplification was evidenced in bronchial dysplasia with a role in cellular proliferation, but not in the progression to invasive carcinoma [37, 38]. In addition, HER2 overexpression was documented in breast ductal carcinoma in situ with negative prognostic significance, but not in benign and atypical proliferative lesions [39, 40].

Only few studies investigated HER2 overexpression in gastric dysplasia [36, 41–46]. In a series of surgical and biopptic samples, HER2 immunostaining with 2+/3+ score was evidenced in 12.6% of HG-IEN (Figure 1, authors’ collection). Benign gastric mucosa did not show HER2 positivity in any of the specimens, although weak membranous reaction in the foveolae and cytoplasmic staining in specialized glands were observed, as elsewhere previously reported. The comparison of HER2 status between dysplasia and invasive GC showed six cases with concordant 3+ HER2 reactivity and seven with discordant HER2 status; in detail, three cases showed HER2 positivity in the dysplastic epithelium but not in the invasive GC, four cases displayed HER2 overexpression in GC but not in dysplasia [46]. It may be argued that the possible discordant HER2 status between paired dysplasia and GC should indicate that extrapolation of HER2 status of invasive carcinoma based on that observed in dysplasia is not reliable. Moreover, it may pose practical difficulties in assessing HER2 expression in biopsies with high-grade dysplasia transiting to carcinoma, determining false positive results in biopsies, due to the misinterpretation of HER2-positive dysplasia as invasive carcinoma [46].

HER2 overexpression has been also documented in LG-IEN, although with significantly lower frequency (4–8%) compared to that found in HG-IEN (16–20%) [41–43]. On the whole, these findings suggest that HER2 overexpression characterizes the early steps of gastric carcinogenesis [41–43]. However, the absence of HER2 overexpression in invasive GC matching HER2-positive dysplasia indicates that this
molecular deregulation may involve only a subset of cells in the intraepithelial neoplastic population [42].

By using immunohistochemistry, gastric dysplasia has been also classified into adenomatous/type I (intestinal phenotype), which is characterized by immunostaining for CD10 and CDX2; foveolar or pyloric/type II (gastric phenotype), which shows staining for MUC5AC and MUC6 and absence of CD10 expression; hybrid, which displays a mixed phenotype; null, when none of the aforementioned markers is expressed [47–50]. HER2 amplification was observed in cases classified as gastric or hybrid, which suggests that this type of dysplasia may represent the precursor of gastric type adenocarcinoma originating de novo from gastric mucosa [50]. An extensive analysis of HER2 status in immunoclassified gastric dysplasia may help to identify those patients at higher risk to develop a specific type of cancer, although the relationship between HER2 overexpression and progression of dysplasia to GC still requires further investigation.

3. HER2 in Early Gastric Cancer

There is some evidence that the identification of precursor lesions may be helpful for the early diagnosis of GC [51]. In Japan and Korea, endoscopy-based population screening allows frequent detection of early gastric cancer (EGC), which can be a suitable candidate for conservative treatments such as endoscopic submucosal dissection [51]. EGC is defined, irrespectively of the tumor size, as a carcinoma invading the mucosa and/or submucosa with or without lymph node metastases [52]. The incidence of nodal metastases in EGC depends upon the size, depth of invasion in the gastric wall, and histological differentiation of the tumor [53–55]. In detail, the incidence of nodal involvement is 0% for well-differentiated tumors of less than 2 cm in size and restricted to gastric mucosa, while it is higher than 30% for tumors showing infiltration in the submucosa, poor differentiation, and size larger than 2 cm [53–55].

According to the macroscopic classification of Japanese Endoscopic Society, EGC is divided into Type I, which includes tumors with polypoid growth, Type II which comprises tumors with superficial growth, Type III which describes tumors with excavating growth, and Type IV which refers to tumors with infiltrative growth and lateral spreading. Then, Type II EGC is further subdivided into IIa (elevated), IIb (flat), and IIc (depressed) and, on microscopic viewpoint, the most common histological architecture found in EGC is well differentiated, tubular, and/or papillary pattern [56]. For this reason, it may be challenging at times to discriminate between well-differentiated adenocarcinoma and high grade dysplasia, especially in superficial specimens of gastric mucosa [56]. EGC has good prognosis, with 5-year survival rate around 90% for N0 tumors [57] and around 70–75% for N+ carcinomas [57].

The presence of lymph node metastases is the main factor conditioning the surgical procedure for the resection of EGC. Indeed, according to the National Comprehensive Cancer Network guidelines [58], EGC without lymph node metastases can be a suitable candidate to endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) [55, 59, 60]. The size, histological type, depth of invasion, and lymphatic or venous invasion of the primary tumor were evidenced as factors predictive of nodal metastases in EGC [61–65]. With reference to molecular alterations, microsatellite instability (MSI), mutations in the p53 gene and overexpression of the epidermal growth factor receptor (EGFR) and HER2 genes seem to have a prognostic role in EGC. In detail, high microsatellite instability (MSI-H), a form of genomic instability associated with defective DNA mismatch repair, was demonstrated in EGC with a frequency ranging between 8.2% and 37% [65–67] and it was shown as an independent predictor of low frequency of lymph node metastases and long survival in this subset of tumors [65, 68]. On the other hand, mutation in the p53 gene, which is one of the most frequent genetic abnormalities observed in GC, was associated with nodal metastases in EGC [65]. Finally, overexpression of EGFR and HER2 genes was significantly correlated with disease recurrence and poor prognosis in patients affected by EGC [65, 69, 70]. As a matter of fact, patients with HER2-negative pN0 EGC have significantly higher 5-year overall survival (91.1%) compared to patients with HER2-positive (Figure 2, authors’ collection) pN0 EGC (81.8%) [60]. In addition, HER2 immunoexpression appears to be significantly associated with development of micrometastases in pN0 EGC [60, 71].

4. HER2 in Advanced Gastric Cancer

According to the published literature, HER2 overexpression/amplification, assessed by immunohistochemistry and/or in situ hybridization, ranges between 7% and 34% in advanced GC [72–78]. Of note, based on the results of an international randomized controlled trial (ToGA), patients with advanced gastric adenocarcinoma overexpressing HER2 are eligible for target treatment with Trastuzumab [22, 79]. Indeed a significant reduction of mortality rate was observed in patients with HER2 overexpressing advanced GC treated with combined chemotherapy and Trastuzumab [22, 79]. On the whole, HER2 positivity is significantly more frequent in gastroesophageal junction cancer (24–35%) compared to GC (9.5–21%) [73, 78, 80, 81]. Moreover, the rate of HER2 overexpression varies according to the histotype of GC [73, 75–77, 80],
with higher frequency evidenced in the intestinal histotype (81.6%–91%) compared to the diffuse or mixed (4%–7.9%) [77, 82–85]. Of note, the pattern of HER2 immunoreactivity is frequently heterogeneous in intestinal GC, which showed intermingled HER2-positive and HER2-negative areas. On the other hand, a more uniform unreactive HER2 pattern was encountered in diffuse histotype. Interestingly, HER2 overexpression rate progressively increases moving from the poorly cohesive WHO histotype to the mitochondrion-rich adenocarcinoma (MRC), tubular adenocarcinoma, and hepatoid carcinoma (HAS) [74, 76] which has the highest frequency of HER2 positivity and the worst prognosis [74, 76]. HER2 overexpression is also significantly associated with high histological grade, high Ki-67 labeling index (LI), and advanced stage [78]; thus it represents an additional morphological parameter reflecting aggressiveness of GC [78]. The biological reasons for the peculiar association between HER2 overexpression and the histotype of GC have not been yet fully elucidated and additional investigation is required. However, a possible explanation for this phenomenon may reside in the relationship between e-cadherin and HER2 expression. Indeed HER2 amplification is inversely associated with e-cadherin mutations [75, 86], and e-cadherin mutations are frequent in diffuse gastric and lobular breast carcinoma and rare in intestinal and ductal breast cancer [73, 75].

HER2 overexpression/amplification is frequently heterogeneous in GC [46, 87, 88] compared to breast cancer, in which HER2 heterogeneity is uncommon [89, 90]. For this reason, several recommendations on methodology, interpretation, and quality control for HER2 testing in GC have been proposed, especially with regard to the assessment in biopic specimens of surgically unresectable cases. In addition, criteria for the assessment of HER2 amplification in biopic and surgical specimens of GC have been significantly modified from those routinely applied to breast carcinoma [91]. In particular, the guidelines for the assessment of HER2 status in GC state that the staining intensity (light, moderate, and strong) and distribution (complete, lateral, and basolateral) at cell membrane should be evaluated in at least 10% of neoplastic cells in surgical specimens and in a cluster of at least 5 tumor cells in the biopsy [77, 82, 87] (Table 1). This HER2 scoring system represents a reliable tool for the evaluation of HER2 status in GC biopsy and surgical specimen, and it results in good concordance between paired biopsy and surgical specimen of advanced GC, mainly if all the available specimens are tested [46, 77, 92–96]. Nonetheless, a low rate of HER2 discordance has been reported between paired biotic and surgical samples of GC [97].

No guidelines are currently available on the number of tumor blocks to be tested for HER2 expression. However it was proposed that more than one (at least three) representative tumor blocks, obtained from different neoplastic areas, should be analyzed in order to overcome HER2 heterogeneity [82, 92, 98]. Moreover, it was suggested that at least 6 to 8 tumor fragments are required for adequate assessment in biopsies, mainly in patients who have low chance of being submitted to surgery [46, 77].

Recently, several studies addressed the issue of HER2 concordance between primary carcinoma and its metastases (Figures 3 and 4, authors’ collection). Indeed it was shown that HER2 status may differ between primary tumor and matched metastases in both breast and stomach cancers [99–108]. Although a preliminary report did not show any significant changes in HER2 status in metastatic lesions compared to primary GC [84], more recent data demonstrated discordant HER2 status between primary carcinoma and synchronous or metachronous locoregional/distant metastases, with a mean rate of 7% and either positive or negative conversion [41, 99, 101, 104, 109–113]. In addition, changes in HER2 status, consisting in either positive or negative conversion, were evidenced in a comparative analysis between paired primary GC and corresponding synchronous metastatic lymph nodes in patients who did not receive adjuvant chemotherapy [101, 104, 108]. This latter fining may have relevant clinical impact [108]. Indeed, if HER2 expression is tested only in the primary GC, a percentage of patients with HER2-positive conversion in lymph node metastases may be excluded from targeted therapy [108]. Positive conversion may be related to the development of a HER2-positive subclone in metastatic lymph nodes as a result of disease progression [108]. On the other hand, negative conversion observed in metastatic deposits of patients who had not received any neoadjuvant treatments [108] cannot develop as the result of resistance to Trastuzumab therapy. Of note, discrepancy in HER2 status between primary tumor and paired nodal metastases was already highlighted in breast cancer [106, 107]. Although at

<table>
<thead>
<tr>
<th>Surgery</th>
<th>Biopsy</th>
<th>HER2 score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No reactivity or membranous reactivity in &lt;10% of tumor cells</td>
<td>No reactivity in any tumor cell</td>
<td>Negative (0)</td>
</tr>
<tr>
<td>Faint or barely detected membranous reactivity in ≥10% tumor cells</td>
<td>Tumor cell cluster of ≥5 cells with faint or barely detected membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Negative (1+)</td>
</tr>
<tr>
<td>Weak to moderate complete, basolateral, or lateral membranous reactivity in ≥10% tumor cells</td>
<td>Tumor cell cluster of ≥5 cells with weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Equivocal (2+)</td>
</tr>
<tr>
<td>Strong complete, basolateral, or lateral membranous reactivity in 10% or more of tumor cells</td>
<td>Tumor cell cluster of ≥5 cells with strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Positive (3+)</td>
</tr>
</tbody>
</table>

TABLE 1: Immunohistochemical criteria for HER2 scoring in neoplastic specimens of the stomach.
present there is no indication of testing HER2 status in synchronous nodal metastases from GC, possible discordance in HER2 expression in metastatic tumors compared to primitive cancer is relevant for the therapeutic management and prognosis of the patients. Indeed further patients eligible for Trastuzumab-based therapy may be identified by assessing HER2 status in synchronous metastases from patients with HER2-negative primary GC.

5. Conclusions

HER2 putative role in gastric carcinogenesis still needs investigation. The evidence of a higher rate of HER2 overexpression in gastric HG-IEN compared to LG-IEN suggests that HER2 may be involved in the early steps of gastric carcinogenesis. In accordance, GC showing CIN, frequent amplification of genes related to receptor tyrosine kinase RTK/RAS signaling such as HER2, and Lauren’s intestinal type has been recognized as a distinct molecular subtype of GC [19, 114].

Although HER2 has emerged as a new therapeutic target in GC, its role as a prognostic marker in this tumor is still controversial [115–121]. Indeed, some studies demonstrated that HER2 overexpression is a poor prognostic factor in GC [122, 123], while others showed that it may be favorable or irrelevant for prognosis [85, 123, 124]. In view of the correlation between HER2 overexpression and the immunohistochemical subtype of gastric dysplasia, HER2 assessment in gastric dysplasia may be helpful in order to identify patients at increased risk of developing a specific type of cancer. In addition, in our opinion, HER2 testing can be used as a prognostic factor to predict the risk of poor outcome in EGC,
since patients with HER2-negative pN0 EGC have significantly higher 5-year overall survival compared to patients with HER2-positive pN0 EGC [60].

In advanced GC, HER2 overexpression is significantly more frequent in tumors showing tubular histotype, high histological grade, advanced stage, and high Ki-67 LI, which suggests that it may represent an additional prognostic negative parameter. Finally, in view of the possible difference in HER2 status between primary GC and synchronous lymph node metastases, we suggest that HER2 status is routinely assessed not only in primary GC, but also in nodal and distant metastases, in order to identify possible candidates eligible for targeted Trastuzumab therapy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References


Disease Markers

taging and gastric cancer risk: a twelve-year clinico-patholog-
ical follow-up study,” Alimentary Pharmacology and Thera-

[29] M. Rugge, F. Farinati, R. Baffa et al., “Gastric epithelial dys-
plasia in the natural history of gastric cancer: a multicenter
prospective follow-up study. Interdisciplinary Group on Gastric
Epithelial Dysplasia,” Gastroenterology, vol. 107, no. 5, pp. 1288–

invasive neoplasia lesions in gastric intestinal metaplasia: the
immunophenotype,” Journal of Clinical Pathology, vol. 60, no.

[31] P. Correa, M. B. Piazuelo, and K. T. Wilson, “Pathology of gas-
tric intestinal metaplasia: clinical implications,” The American

profiling of gastric intraepithelial neoplasia and early-stage

[33] G. Testino, “Gastric precancerous changes: carcinogenesis,
clinical behaviour immunophenotype study and surveillance,”

[34] L.-L. Lin, H.-C. Huang, and H.-F. Juan, “Discovery of biomark-
ers for gastric cancer: a proteomics approach,” Journal of

K.-L. Sun, “Studies of promoter methylation status and protein
expression of E-cadherin gene in associated progression stages
of gastric cancer,” Yichuan Xuebao, vol. 30, no. 2, pp. 103–108,
2003.

[36] E. Rossi, S. Grisanti, V. Villanacci et al., “HER-2 overexpres-
sion/amplification in Barrett’s oesophagus predicts early tran-
slion from dysplasia to adenocarcinoma: a clinico-pathologic
study,” Journal of Cellular and Molecular Medicine, vol. 13, no.

[37] D. T. Merrick, J. Kittelson, R. Winterhalder et al., “Analysis of
c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2
expression in bronchial dysplasia: evaluation of potential targets
for chemoprevention of lung cancer,” Clinical Cancer Research,

[38] M. J. van de Vijver, J. L. Peterse, W. J. Mooi et al., “Neu-protein
overexpression in breast cancer. Association with comedo-type
ductal carcinoma in situ and limited prognostic value in stage
II breast cancer,” The New England Journal of Medicine, vol. 319,

and V. A. LiVolsi, “Immunohistochemical evaluation of c-erbB-
2 oncogene expression in ductal carcinoma in situ and atypical
ductal hyperplasia of the breast,” Modern Pathology, vol. 3,

[40] M. Van Bockstal, K. Lambein, H. Denys et al., “Histopatholog-
cal characterization of ductal carcinoma in situ (DCIS) of the
breast according to HER2 amplification status and molecular

[41] N. Fusco, E. G. Rocco, C. Del Conte et al., “HER2 in gastric
cancer: a digital image analysis in pre-neoplastic, primary and
metastatic lesions,” Modern Pathology, vol. 26, no. 6, pp. 816–
824, 2013.

[42] M. Fassan, L. Mastracci, F. Grillo et al., “Early HER2 dysregu-
lation in gastric and oesophageal carcinogenesis,” Histopathology,
vol. 61, no. 5, pp. 769–776, 2012.

trastuzumab in dysplasia and adenocarcinoma arising in Bar-
rett’s esophagus: a translational approach,” Minerva Gastroen-

[44] E. Rossi, V. Villanacci, G. Bassotti et al., “TOPOIIalpha and
HER-2/neu overexpression/amplification in Barrett’s oesopha-

[45] Y. Hu, S. Bandla, T. E. Godfrey et al., “HER2 amplification,
overexpression and score criteria in esophageal adenocarcinoma,”

[46] S. Lee, W. B. de Boer, S. Fermoyle, M. Platten, and M. P.
Kumarasinghe, “Human epidermal growth factor receptor 2
testing in gastric carcinoma: issues related to heterogeneity in
biopsies and resections,” Histopathology, vol. 59, no. 5, pp. 832–
840, 2011.

[47] A. M. M. F. Nogueira, J. C. Machado, F. Carneiro, C. A. Reis,
P. Gött, and M. Sobrinho-Simões, “Patterns of expression of trefoil
peptides and mucins in gastric polyps with and without malign-

foveal gastric dysplasia: distinct patterns of mucin expression and
background intestinal metaplasia,” The American Journal of Surgical

the intestinal-type gastric epithelial neoplasia: frequency and

[50] P. Valente, M. Garrido, I. Gullo et al., “Epithelial dysplasia of
the stomach with gastric immunophenotype shows features of
biological aggressiveness,” Gastric Cancer, 2014.

[51] J. H. Kang, Y. J. Lim, J. H. Kang et al., “Prevalence of precanc-
erous conditions and gastric cancer based upon the national
cancer screening program in Korea for 7 years, single center
experience,” Gastron Gastroenterology and Practice, vol. 2015,
Article ID 571965, 5 pages, 2015.

[52] B. Hu, N. El Hajj, S. Sittler et al., “Gastric cancer: classification,
histology and application of molecular pathology,” Journal of

tasis in undifferentiated early gastric cancer,” Annals of Surgical

node metastasis and the feasibility of endoscopic resection for
undifferentiated-type early gastric cancer,” Gastric Cancer, vol.

Carvalho, “Lymph node metastasis in early gastric cancer,”
Revista do Colegio Brasileiro de Cirurgios, vol. 41, no. 1, pp. 11–17,
2014.

of signet ring cell carcinoma is more amenable to endoscopic
therapy than is early gastric cancer of poorly differentiated
tubular adenocarcinoma in select tumor conditions,” Surgical
Endoscopy and Other Interventional Techniques, vol. 25, no. 9,

[57] Y. Isobe, A. Nashimoto, K. Akazawa et al., “Gastric cancer
treatment in Japan: 2008 annual report of the JGCA nationwide

[58] A. A. Ajani, J. S. Barthel, D. J. Bentrem et al., NCCN Clinical
Practice Guidelines in Oncology (NCCN GuidelinesTM). Gastric
Cancer (Including Cancer in the Proximal 5 cm of the Stomach),


Disease Markers


